№ files_lp_4_process_3_116797
File format: docx
Character count: 2795
File size: 72 KB
The document provides a detailed explanation of the OPAL Resubmission process for teachers, including guidelines on submitting failed strands and a reflection on professional learning.
Note:
Year
Subject:
Professional Learning
Document Type:
Guideline
Target Audience:
Teachers
Period of Validity:
One calendar year from original submission
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
Cornwall, UK
Theme:
Healthcare, Frailty Management
Document Type:
Pathway Guidelines
Organization:
Acute GP Cornwall
Author:
Acute GP Cornwall
Target Audience:
Healthcare professionals working with older adults and frail patients
Action Period:
Ongoing
Approval Date:
Not specified
Modification Date:
Not specified
Note:
Context
Year:
2024
Region / City:
USA
Subject:
Permitting System Tutorial
Document Type:
User Guide
Organization / Institution:
Oracle
Author:
Not specified
Target Audience:
General public, permit applicants
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Institution:
Bournemouth University
System:
OPAL (Online Practice Assessment for Learning)
Document Type:
Guidance leaflet
Subject Area:
Health and Social Care education and clinical placement assessment
Relevant Standards:
NMC Standards for Student Supervision and Assessment (SSSA)
Target Users:
Practice Supervisors, Practice Assessors, Academic Assessors, BU Academic Advisors, Student Midwives
Associated Programme:
Midwifery education programme
Implementation Context:
Clinical placements and academic assessment
Original Implementation of OPAL:
November 2014
Related System Replaced:
Paper Practice Assessment Documents (PAD)
Access Method:
Web-based system via www.opalbu.com
Institutional Affiliation:
Bournemouth University Health and Social Care placements system
Key Roles Referenced:
Practice Supervisor, Practice Assessor, Academic Assessor, Personal Academic Advisor
Professional Registration Reference:
NMC registration number required for users
Usage Environment:
Hospitals, clinics, or any internet-connected device
Support Resources:
OPAL webpages and dedicated OPAL support helpdesk
Programme Levels Referenced:
Level 4, Level 5, Level 6 of the programme
Assessment Components:
Initial interview, mid-placement interview, final interview, skills assessment, formative and summative competence assessment, placement documentation
Year:
2026
Region / City:
Not specified
Theme:
School activities, play and learning
Document Type:
Letter to parents/carers
Organization / Institution:
OPAL program
Author:
C Poulson / Miss Poulson
Target Audience:
Parents/Carers of students
Activity Period:
Spring Term 2026
Start Date:
19th January 2026
End Date:
20th February 2026
Rewards:
OPAL playtime for completing Bingo lines
Special Items:
STAR item for additional reward
Year:
2026
Region / City:
United States
Theme:
Personal experiences and reflections
Document type:
Excerpt from a literary work with discussion prompts
Author:
Kate DiCamillo
Target audience:
Young readers / Students
Chapters:
5-6
Related activities:
Writing and reflection exercises
Language:
English
Year:
2023
Region / city:
Australia
Topic:
Oncology, Pharmaceuticals
Document Type:
Resubmission
Institution:
Australian Government, Pharmaceutical Benefits Advisory Committee
Author:
AstraZeneca Pty Ltd.
Target Audience:
Healthcare professionals, regulatory bodies
Effective Period:
Ongoing
Approval Date:
November 2021
Date of Changes:
November 2021
Note:
Year
Document Type:
Assessment Form
Institution:
Pearson
Author:
Pearson
Target Audience:
Students, Assessors
Year:
2022
Country:
Australia
Therapeutic area:
Oncology
Disease:
Endometrial cancer
Biomarker status:
Mismatch repair deficient (dMMR)
Medicine name:
Dostarlimab
Brand name:
Jemperli
Dosage form:
Solution concentrate for intravenous infusion
Sponsor:
GlaxoSmithKline Australia Pty Ltd
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission type:
Standard Re-entry submission
Requested listing:
Section 100
Comparator treatments:
Standard of care chemotherapy; pembrolizumab plus lenvatinib; pembrolizumab monotherapy
Clinical trial referenced:
GARNET
Approval status:
Provisional approval
Indication:
Recurrent or advanced endometrial cancer after platinum-containing regimen
Decision context:
PBS listing consideration
Period covered:
Up to November 2022
Drug name:
Apremilast
Brand name:
Otezla
Dosage form:
Tablet
Strength:
30 mg
Pack composition:
4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg
Sponsor:
Amgen Australia Pty Ltd
Regulatory status:
TGA registered
TGA registration date:
19 March 2015
Indication:
Severe plaque psoriasis
Previous indication:
Psoriatic arthritis and moderate to severe plaque psoriasis
Application type:
Minor resubmission
Requested listing:
PBS General Schedule, Authority Required (STREAMLINED)
Comparator:
Cyclosporin
Clinical population:
Patients with severe plaque psoriasis intolerant of or contraindicated to methotrexate
Primary outcome:
PASI-75 at 16 weeks
Clinical claim:
Non-inferior comparative efficacy and safety versus cyclosporin
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission history period:
2015–2018
Geographic scope:
Australia
Source type:
Public summary document excerpt
Year:
2019–2020
Region / country:
Australia
Subject:
Chronic migraine treatment and drug listing
Document type:
Public Summary Document (PSD)
Organization / authority:
Pharmaceutical Benefits Advisory Committee (PBAC), TGA
Drug:
Galcanezumab (Emgality)
Other drugs referenced:
Fremanezumab, Erenumab, Botox
Target population:
Adults with chronic migraine unresponsive to at least three prophylactic migraine medications
Administration form:
Injection 120 mg/1 mL pre-filled pen
Prescription restrictions:
Streamlined listing, treatment by neurologist required, specific clinical criteria for migraine frequency and prior treatment response
Consumer input:
Included 186 individuals, 2 health professionals, 1 organization
Cost analysis:
Cost-minimisation analysis (CMA) versus Botox
Risk sharing arrangement:
Included, with expenditure cap adjustments
Year:
2019
Region / city:
Australia
Theme:
Oncology, Chemotherapy
Document type:
Resubmission for PBS listing
Organ / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Bristol-Myers Squibb Australia Pty Ltd
Target audience:
Medical professionals, PBAC members
Validity period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Medicine:
Midazolam oromucosal solution in pre-filled syringe
Brand name:
Zyamis®
Sponsor:
Clinect Pty Ltd
Dosage forms:
2.5 mg/0.25 mL; 5 mg/0.5 mL; 7.5 mg/0.75 mL; 10 mg/1 mL
Indication:
Treatment of generalised convulsive status epilepticus (GCSE) in patients over 6 months of age
Regulatory authority:
Therapeutic Goods Administration (TGA)
ARTG listing date:
22 April 2022
Advisory body:
Pharmaceutical Benefits Advisory Committee (PBAC)
Submission type:
Early re-entry resubmission
Requested listing:
Section 85 Authority Required (telephone/online)
Additional request:
Prescriber Bag Schedule listing for Medical Practitioners
Comparative medicine:
Midazolam hydrochloride injection 5 mg/mL
Proposed maximum quantity:
2 pre-filled syringes per prescription
Estimated financial impact:
$20 million to < $30 million over six years
Previous consideration:
July 2022 PBAC meeting
Source:
Public Summary Document (PSD), July 2022
Year:
2021
Region / City:
Australia
Document Type:
Public Summary Document (PSD)
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Not specified
Target Audience:
Healthcare professionals, Medical Practitioners
Period of Effect:
2021-2022
Approval Date:
15 July 2021
Revision Date:
November 2021
Year:
2026
Region / city:
Colorado
Theme:
Education, Curriculum Design
Document Type:
Guidelines, Course Proposal
Institution:
Colorado State University
Author:
Curriculum & Catalog Unit
Target Audience:
Faculty, Academic Administrators, Curriculum Committees
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Year
Topic:
Diversity, Equity, and Inclusion
Document Type:
Course Proposal
Institution:
Colorado State University
Target Audience:
CSU faculty, curriculum committees, and academic departments
Year:
2023
Region / City:
Australia
Topic:
Oncology, Haematology, Pharmaceutical Submission
Document Type:
Submission Request
Organisation:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Amgen Australian Pty Ltd
Target Audience:
Healthcare professionals, Pharmaceutical industry
Period of Validity:
Ongoing
Approval Date:
N/A
Date of Changes:
N/A
Year:
2021
Region / city:
South Gloucestershire, Kingswood
Topic:
Planning Application
Document Type:
Consultation Response
Organization / Institution:
The Coal Authority
Author:
James Smith
Target Audience:
Case Officer, Local Planning Authorities
Period of validity:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
United Kingdom
Subject:
Professional supervision and accreditation
Document type:
Guidance form
Organization / Institution:
British Association for Counselling and Psychotherapy (BACP)
Author:
BACP Accreditation Department
Target audience:
Supervisors and applicants for accreditation
Purpose:
To provide instructions for completing a supervisor statement as part of the accreditation resubmission process
Relevant legislation:
GDPR, Data Protection Act 2018
Sections included:
Applicant details, Supervisor details, Supervision contract, Comments, Signatures
Format:
Digital form for online submission
Year:
2026
Institution:
Orthopaedic outpatient clinic
Document type:
Medical case report
Authors:
Multiple, corresponding author indicated
Patient age:
40
Patient gender:
Male
Patient smoking status:
Smoker
Medical condition:
Recurrent giant-cell tumor of proximal humerus with pulmonary metastasis
Procedures:
Wide excision, hemiarthroplasty using Austin Moore prosthesis
Histopathology results:
Postoperative biopsy showed recurrent giant-cell tumor, no sign of malignancy initially; malignant GCT after shoulder disarticulation
Infection:
S. aureus, treated with specific antibiotics
Consent:
Informed consent obtained from patient
Follow-up outcome:
Patient deceased 2 years post-disarticulation due to loss of follow-up and missed chemotherapy
Imaging:
X-ray, CT scans partially performed, some unavailable
References:
Added discussion and references following JKKI style